ArticleWorld journal of gastroenterology2005
Clinical evaluation of serum concentrations of intercellular adhesion molecule-1 in patients with colorectal cancer.
Article in World journal of gastroenterology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 14 citations in OpenAlex.
- Exploring the evolving function of soluble intercellular adhesion molecule-1 in junction dynamics during spermatogenesis.Frontiers in endocrinology · 2023Review
- Roles of intercellular cell adhesion molecule-1 (ICAM-1) in colorectal cancer: expression, functions, prognosis, tumorigenesis, polymorphisms and therapeutic implications.Frontiers in oncology · 2022Review
- Soluble intercellular adhesion molecule-1 is a prognostic marker in colorectal carcinoma.International journal of colorectal disease · 2019Article
- Identification of key pathways and biomarkers in sorafenib-resistant hepatocellular carcinoma using bioinformatics analysis.Experimental and therapeutic medicine · 2018Article
- Impacts of ICAM-1 gene polymorphisms on urothelial cell carcinoma susceptibility and clinicopathologic characteristics in Taiwan.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
- Activation of AMP-activated protein kinase attenuates hepatocellular carcinoma cell adhesion stimulated by adipokine resistin.BMC cancer · 2014Article
- CXC chemokine ligand 12/stromal cell-derived factor-1 regulates cell adhesion in human colon cancer cells by induction of intercellular adhesion molecule-1.Journal of biomedical science · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo investigate the correlation between the serum soluble intercellular adhesion molecule-1 (sICAM-1) and the clinicopathologic features and to evaluate the possible prognostic significance of sICAM-1 concentration in colorectal cancer.
methodsA total of 56 patients (mean age 57.3 years) having transitional cell carcinoma of the colorectal and 25 control patients (mean age 42.6 years) were enrolled in the study. The serum samples of the patients were obtained on the day before surgery. Sera were obtained by centrifugation, and stored at -80 degrees C until assay. Serum concentrations of ICAM-1 were measured with enzyme-linked immunoassay. Differences between the two groups were analyzed by Student's t-test.
resultsNo significant increase of serum sICAM-1 could be demonstrated in the Dukes A(1) patients (352.63+/-61.82 mug/L) compared to the control group (345.72+/-49.81 microg/L, P>0.05), Dukes A(1) patients (352.63+/-61.82 microg/L) compared to Dukes A(2,3) patients (491.17+/-86.36 microg/L, P<0.05). Furthermore, the patients with Dukes B had significantly higher serum concentrations of sICAM-1 than those of the control group (496.82+/-93.04 microg/L vs 345.72+/-49.81 microg/L, P<0.01). Compared with Dukes A(2,3), B colorectal cancer patients, patients with more advanced clinical stage (Dukes C and D) had higher levels of sICAM-1 (743.68+/-113.74 microg/L vs 491.17+/-86.36 microg/L and 496.82+/-93.04 microg/L, P<0.001). The difference was statistically significant in sICAM-1 levels between patients with positive lymph node status and those without lymph node involvement (756.25+/-125.57 microg/L vs 445.62+/-69.18 microg/L, P<0.001). Patients with poorly differentiated colorectal cancer had a higher level of sICAM-1 than those with differentiated and highly differentiated cancer (736.49+/-121.97 microg/L vs 410.23+/-67.47 microg/L, P<0.001).
conclusionIn this study, serum ICAM-1 levels were found to be related to tumor presence, clinical stages, and grade. Increased ICAM-1 in patients with colorectal cancer which should be considered when the diagnostic and/or prognostic usefulness of soluble ICAM-1 is to be evaluated. sICAM-1 should prove useful for monitoring malignant disease stage and for evaluating the effectiveness of various therapeutic approaches for colorectal carcinomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.